Gene Knock down (RNAi) |
|
RNA interference (RNAi) is a mechanism in which double-stranded RNAs inhibits corresponding gene expression by inducing degradation of its mRNA.
RNAi approaches have become state-of-the-art methods for in vitro target validation.
|
|
Invitrogen Corporation and genOway are working together to provide
a complete RNAi solutions platform for the in vivo use of shRNA to researchers worldwide
Click here for more information
|
|
|
|
genOway has developed a panel of technologies that secures in vivo gene Knock-down. |
 |
|
Random insertion of the shRNA construct into the mouse genome |
|
|
 |
shRNA copy number is controlled |
|
Access to high numbers of founders to avoid shRNA position effects |
|
Short development time (similar to DNA microinjection) |
|
|
The offer genOway has developed can include the following steps, but the service is flexible (can be limited to part of this offer and/or adapted to customer requirements) |
|
| Step 1 : |
Construction of the shRNA expression vector |
| Step 2 : |
Random integration of the shRNA expression vector |
| Step 3 : |
Blastocyst injection and chimera generation |
| Step 4 : |
Breeding to the F1 and F2 generation |
|
|
Targeted insertion of the shRNA construct into the mouse genome |
|
The " Safe in vivo RNAi™" technology enables a targeted insertion (knock-in) of the shRNA construct and secures its expression: |
|
Access to ready-to-use targeting vectors suitable for spatio-temporal control of shRNA expression |
|
For in vivo validation of shRNA and relevant comparative studies |
|
The target gene can be subsequently removed to study shRNA off-target effects. |
|
|
|
Intellectual Property
Knock-in is a general term for models expressing a transgene targeted in a
selected locus. Several technologies exist to create such models. These
technologies use techniques (alone or in combination) such as homologous
recombination, recombinases, insertion shuttles, etc.
genOway can implement technologies that are free of use for customers and in
particular that are not depending from the Pasteur Institute patent family
(abusively called Homologous recombination technology by Cellectis).
|
|
The offer genOway has developed can include the following steps, but the service is flexible (can be limited to part of this offer and/or adapted to customer requirements) |
|
| Step 1 : |
Insertion of the shRNA of interest into genOway ready-to-use knock-in vector |
| Step 2 : |
Homologous recombination in Embryonic Stem cells (ES Cell) |
| Step 3 : |
Blastocyst injection and chimera generation |
| Step 4 : |
Breeding to the F1 and F2 generation |
|
 | |
|
|
Service offer
Ready-to-use models